Valuation Highnoon Laboratories Limited

Stocks

End-of-day quote Pakistan S.E. 2026-10-22			5-day change	1st Jan Change
921.27 ^PKR	-1.04%		+0.55%	-9.90%

08-27	Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-18	Highnoon Laboratories Appoints Dr. Shahzad Khan as Managing Director of Highnoon Life Sciences	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027	2028
Market Cap ¹	48,650	54,175	48,812	-	-
Change	-	11.36%	-9.9%	-	-
Enterprise Value (EV)	48,650	54,175	48,812	48,812	48,812
Change	-	11.36%	-9.9%	0%	0%
P/E	14.4x	-	-	-	-
PBR	-	-	-	-	-
PEG	-	-	-	-	-
Capitalization / Revenue	-	1.96x	1.61x	1.43x	1.27x
EV / Revenue	-	0x	1.61x	1.43x	1.27x
EV / EBITDA	-	-	-	-	-
EV / EBIT	-	-	-	-	-
EV / FCF	-	-	-	-	-
FCF Yield	-	-	-	-	-
Dividend per Share ²	-	50	45	52	60
Rate of return	-	4.89%	4.88%	5.64%	6.51%
EPS ²	63.95	-	-	-	-
Distribution rate	-	-	-	-	-
Net sales ¹	-	27,706	30,398	34,163	38,399
EBITDA	-	-	-	-	-
EBIT	-	-	-	-	-
Net income	3,389	-	-	-	-
Net Debt	-	-	-	-	-
Reference price ²	918.22	1,022.49	921.27	921.27	921.27
Nbr of stocks (in thousands)	52,983	52,983	52,983	-	-
Announcement Date	3/26/25	4/7/26	-	-	-

¹PKR in Million²PKR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
HIGHNOON LABORATORIES LIMITED	-	-	-	4.83%	178M
ELI LILLY AND COMPANY	36.67x	13.07x	27.74x	0.54%	1,133B
JOHNSON & JOHNSON	37.73x	6.36x	17.89x	2.07%	621B
ABBVIE INC.	36.35x	8.36x	17.26x	2.41%	503B
ROCHE HOLDING AG	21.21x	5.12x	12.74x	2.55%	379B
MERCK & CO., INC.	109.25x	6.09x	26.14x	2.27%	370B
NOVARTIS AG	21.57x	5.62x	13.82x	2.84%	292B
ASTRAZENECA PLC	22.08x	4.46x	12.77x	1.98%	262B
AMGEN INC.	27.83x	7.14x	12.79x	2.3%	237B
GILEAD SCIENCES, INC.	-44.76x	6.88x	26.67x	2.15%	190B
Average	29.77x	7.01x	18.64x	2.39%	398.82B
Weighted average by Cap.	35.57x	8.27x	20.36x	1.81%